Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
Clinical trial NCT06125197 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06125197
- Sponsor
- TILT Biotherapeutics Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-23
- Primary completion
- 2026-01-30
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.